Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Type of study
Language
Publication year range
2.
Cell Death Differ ; 12 Suppl 1: 916-23, 2005 Aug.
Article in English | MEDLINE | ID: mdl-15719026

ABSTRACT

The envelope glycoprotein complex (Env) of human immunodeficiency virus-1 (HIV-1) can induce apoptosis by a cornucopia of distinct mechanisms. A soluble Env derivative, gp120, can kill cells through signals that are transmitted by chemokine receptors such as CXCR4. Cell surface-bound Env (gp120/gp41), as present on the plasma membrane of HIV-1-infected cells, can kill uninfected bystander cells expressing CD4 and CXCR4 (or similar chemokine receptors, depending on the Env variant) by at least three different mechanisms. First, a transient interaction involving the exchange of lipids between the two interacting cells ('the kiss of death') may lead to the selective death of single CD4-expressing target cells. Second, fusion of the interacting cells may lead to the formation of syncytia which then succumb to apoptosis in a complex pathway involving the activation of several kinases (cyclin-dependent kinase-1, Cdk1; checkpoint kinase-2, Chk2; mammalian target of rapamycin, mTOR; p38 mitogen-activated protein kinase, p38 MAPK; inhibitor of NF-kappaB kinase, IKK), as well as the activation of several transcription factors (NF-kappaB, p53), finally resulting in the activation of the mitochondrial pathway of apoptosis. Third, if the Env-expressing cell is at an early stage of imminent apoptosis, its fusion with a CD4-expressing target cell can precipitate the death of both cells, through a process that may be considered as contagious apoptosis and which does not involve Cdk1, mTOR, p38 nor p53, yet does involve mitochondria. Activation of some of the above- mentioned lethal signal transducers have been detected in patients' tissues, suggesting that HIV-1 may indeed trigger apoptosis through molecules whose implication in Env-induced killing has initially been discovered in vitro.


Subject(s)
Apoptosis , HIV Envelope Protein gp120/pharmacology , HIV-1 , Receptors, Chemokine/drug effects , Animals , CD4 Antigens/drug effects , Cells, Cultured , Gene Products, vpr/pharmacology , Giant Cells/drug effects , Giant Cells/metabolism , HIV Envelope Protein gp120/physiology , HIV-1/pathogenicity , Humans , Mitochondria/drug effects , Mitochondria/metabolism , Receptors, CCR5/drug effects , Receptors, CXCR4/drug effects , Receptors, Chemokine/metabolism , Signal Transduction , vpr Gene Products, Human Immunodeficiency Virus
4.
Cell Death Differ ; 9(12): 1287-93, 2002 Dec.
Article in English | MEDLINE | ID: mdl-12478465

ABSTRACT

The cyclin-dependent kinase 1 (Cdk1), formerly called Cdc2 (or p34(Cdc2)), interacts with cyclin B1 to form an active heterodimer. The activity of Cdk1 is subjected to a complex spatiotemporary regulation, required to guarantee its scheduled contribution to the mitotic prophase and metaphase. Moreover, the activation of Cdk1 may be required for apoptosis induction in some particular pathways of cell killing. This applies to several clinically important settings, for instance to paclitaxel-induced killing of breast cancer cells, in which the ErbB2 receptor kinase can mediate apoptosis inhibition through inactivation of Cdk1. The activation of Cdk1 participates also in HIV-1-induced apoptosis, upstream of the p53-dependent mitochondrial permeabilization step. An unscheduled Cdk1 activation may contribute to neuronal apoptosis occurring in neurodegenerative diseases. Finally, the premature activation of Cdk1 can lead to mitotic catastrophe, for instance after irradiation-induced DNA damage. Thus, a cell type-specific modulation of Cdk1 might be taken advantage of for the therapeutic correction of pathogenic imbalances in apoptosis control.


Subject(s)
Apoptosis/genetics , CDC2 Protein Kinase/metabolism , Eukaryotic Cells/metabolism , Mitosis/genetics , Animals , CDC2 Protein Kinase/genetics , DNA Damage/genetics , DNA Damage/radiation effects , Eukaryotic Cells/cytology , HIV-1/metabolism , HIV-1/pathogenicity , Humans , Neurodegenerative Diseases/genetics , Neurodegenerative Diseases/metabolism
5.
Cell Death Differ ; 9(11): 1212-9, 2002 Nov.
Article in English | MEDLINE | ID: mdl-12404120

ABSTRACT

Previous biochemical studies suggested that HIV-1-encoded Vpr may kill cells through an effect on the adenine nucleotide translocase (ANT), thereby causing mitochondrial membrane permeabilization (MMP). Here, we show that Vpr fails to activate caspases in conditions in which it induces cell killing. The knock-out of essential caspase-activators (Apaf-1 or caspase-9) or the knock-out of a mitochondrial caspase-independent death effector (AIF) does not abolish Vpr-mediated killing. In contrast, the cytotoxic effects of Vpr are reduced by transfection-enforced overexpression of two MMP-inhibitors, namely the endogenous protein Bcl-2 or the cytomegalovirus-encoded ANT-targeted protein vMIA. Vpr, which can elicit MMP through a direct effect on mitochondria, and HIV-1-Env, which causes MMP through an indirect pathway, exhibit additive (but not synergic) cytotoxic effects. In conclusion, it appears that Vpr induces apoptosis through a caspase-independent mitochondrial pathway.


Subject(s)
Apoptosis/physiology , Gene Products, vpr/metabolism , HIV-1/metabolism , Mitochondria/metabolism , Viral Proteins , Apoptosis Inducing Factor , Caspases/metabolism , Cell Line , Cytomegalovirus/metabolism , Flavoproteins/physiology , Gene Products, env/metabolism , Humans , Immediate-Early Proteins/metabolism , Matrix Metalloproteinases/metabolism , Membrane Proteins/physiology , Proto-Oncogene Proteins c-bcl-2/metabolism , Stem Cells , vpr Gene Products, Human Immunodeficiency Virus
6.
J Exp Med ; 194(8): 1097-110, 2001 Oct 15.
Article in English | MEDLINE | ID: mdl-11602639

ABSTRACT

Syncytia arising from the fusion of cells expressing a lymphotropic human immunodeficiency virus (HIV)-1-encoded envelope glycoprotein complex (Env) gene with cells expressing the CD4/CXCR4 complex undergo apoptosis through a mitochondrion-controlled pathway initiated by the upregulation of Bax. In syncytial apoptosis, phosphorylation of p53 on serine 15 (p53S15) precedes Bax upregulation, the apoptosis-linked conformational change of Bax, the insertion of Bax in mitochondrial membranes, subsequent release of cytochrome c, caspase activation, and apoptosis. p53S15 phosphorylation also occurs in vivo, in HIV-1(+) donors, where it can be detected in preapoptotic and apoptotic syncytia in lymph nodes, as well as in peripheral blood mononuclear cells, correlating with viral load. Syncytium-induced p53S15 phosphorylation is mediated by the upregulation/activation of mammalian target of rapamycin (mTOR), also called FKBP12-rapamycin-associated protein (FRAP), which coimmunoprecipitates with p53. Inhibition of mTOR/FRAP by rapamycin reduces apoptosis in several paradigms of syncytium-dependent death, including in primary CD4(+) lymphoblasts infected by HIV-1. Concomitantly, rapamycin inhibits p53S15 phosphorylation, mitochondrial translocation of Bax, loss of the mitochondrial transmembrane potential, mitochondrial release of cytochrome c, and nuclear chromatin condensation. Transfection with dominant negative p53 has a similar antiapoptotic action as rapamycin, upstream of the Bax upregulation/translocation. In summary, we demonstrate that phosphorylation of p53S15 by mTOR/FRAP plays a critical role in syncytial apoptosis driven by HIV-1 Env.


Subject(s)
Apoptosis/immunology , Carrier Proteins , HIV Envelope Protein gp120/immunology , HIV Envelope Protein gp41/immunology , HIV-1/immunology , Immunophilins/immunology , Phosphotransferases (Alcohol Group Acceptor) , Tumor Suppressor Protein p53/immunology , Animals , Giant Cells , HIV Envelope Protein gp120/genetics , HIV Envelope Protein gp41/genetics , HeLa Cells , Humans , Mammals , Phosphorylation , Serine/metabolism , TOR Serine-Threonine Kinases , Transcriptional Activation , Tumor Suppressor Protein p53/genetics , Tumor Suppressor Protein p53/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...